Legal & General Group’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-5,467
Closed -$12.4K 3418
2024
Q2
$12.4K Buy
+5,467
New +$20.9K ﹤0.01% 3234
2023
Q2
Sell
-2,358
Closed -$6.32K 3541
2023
Q1
$6.32K Sell
2,358
-9,213
-80% -$44.3K ﹤0.01% 3269
2022
Q4
$62.8K Buy
+11,571
New +$97K ﹤0.01% 2909
2022
Q2
Sell
-19,837
Closed -$150K 3695
2022
Q1
$150K Buy
19,837
+110
+0.6% +$1.04K ﹤0.01% 2766
2021
Q4
$201K Buy
19,727
+8,986
+84% +$115K ﹤0.01% 2723
2021
Q3
$144K Buy
10,741
+5,805
+118% +$94.6K ﹤0.01% 2775
2021
Q2
$109K Sell
4,936
-100
-2% -$2.22K ﹤0.01% 2705
2021
Q1
$121K Buy
5,036
+456
+10% +$10.6K ﹤0.01% 2567
2020
Q4
$83K Sell
4,580
-181
-4% -$2.7K ﹤0.01% 2639
2020
Q3
$55K Sell
4,761
-1,407
-23% -$23.2K ﹤0.01% 2666
2020
Q2
$149K Buy
6,168
+38
+0.6% +$628 ﹤0.01% 2428
2020
Q1
$68K Sell
6,130
-1,549
-20% -$28.9K ﹤0.01% 2515
2019
Q4
$203K Buy
7,679
+818
+12% +$19.1K ﹤0.01% 2396
2019
Q3
$157K Buy
6,861
+689
+11% +$21.7K ﹤0.01% 2404
2019
Q2
$189K Buy
6,172
+2,112
+52% +$44.5K ﹤0.01% 2362
2019
Q1
$68K Hold
4,060
﹤0.01% 2616
2018
Q4
$78K Buy
4,060
+676
+20% +$25.3K ﹤0.01% 2533
2018
Q3
$177K Buy
3,384
+133
+4% +$7.25K ﹤0.01% 2361
2018
Q2
$141K Buy
3,251
+863
+36% +$37K ﹤0.01% 2388
2018
Q1
$88K Buy
2,388
+628
+36% +$16.8K ﹤0.01% 2510
2017
Q4
$35K Buy
1,760
+455
+35% +$9.78K ﹤0.01% 2988
2017
Q3
$32K Buy
1,305
+1,141
+696% +$21.1K ﹤0.01% 3050
2017
Q2
$3K Buy
+164
New +$2.87K ﹤0.01% 3349

Legal & General Group's GTHX Position: Q3 2024 in Review

Legal & General Group sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2024, closing a stake of 5,467 shares — an estimated $12.4K sold.

Legal & General Group first reported a position in GTHX in Q2 2017 and held it in 23 quarters. The position peaked at $203K in Q4 2019. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.

  • Legal & General Group reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Legal & General Group sold 5,467 G1 Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $12.4K.
  • Legal & General Group first reported a position in G1 Therapeutics, Inc. Common Stock in Q2 2017 and held it in 23 quarters.
  • Legal & General Group's G1 Therapeutics, Inc. Common Stock position peaked at $203K in Q4 2019.
  • 0 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2024.

Based on Legal & General Group's 13F filing for Q3 2024, filed 14 Nov 2024.